Gene therapy of children with X-linked severe combined immune deficiency : efficiency and comlications

被引：8

作者：

Fischer, A ^{[1
]}

Hacein-Bey-Abina, S ^{[1
]}

Cavazzana-Calvo, M ^{[1
]}

机构：

[1] CHU Necker, INSERM, U 429, F-75015 Paris, France

来源：

M S-MEDECINE SCIENCES | 2004年 / 20卷 / 01期

关键词：

D O I：

10.1051/medsci/2004201115

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

[No abstract available]

引用

页码：115 / 117

页数：3

共 10 条

[1] Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning [J].

Aiuti, A ;

Slavin, S ;

Aker, M ;

Ficara, F ;

Deola, S ;

Mortellaro, A ;

Morecki, S ;

Andolfi, G ;

Tabucchi, A ;

Carlucci, F ;

Marinello, E ;

Cattaneo, F ;

Vai, S ;

Servida, P ;

Miniero, R ;

Roncarolo, MG ;

Bordignon, C .

SCIENCE, 2002, 296 (5577) :2410-2413

[2] Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease [J].

Cavazzana-Calvo, M ;

Hacein-Bey, S ;

Basile, CD ;

Gross, F ;

Yvon, E ;

Nusbaum, P ;

Selz, F ;

Hue, C ;

Certain, S ;

Casanova, JL ;

Bousso, P ;

Le Deist, F ;

Fischer, A .

SCIENCE, 2000, 288 (5466) :669-672

[3] Gene therapy of severe combined immunodeficiencies [J].

Fischer, A ;

Hacein-Bey, S ;

Cavazzana-Calvo, M .

NATURE REVIEWS IMMUNOLOGY, 2002, 2 (08) :615-621

[4] Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy [J].

Hacein-Bey-Abina, S ;

Le Deist, F ;

Carlier, F ;

Bouneaud, C ;

Hue, C ;

De Villartay, JP ;

Thrasher, AJ ;

Wulffraat, N ;

Sorensen, R ;

Dupuis-Girod, S ;

Fischer, A ;

Cavazzana-Calvo, M ;

Davies, EG ;

Kuis, W ;

Lundlaan, WHK ;

Leiva, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (16) :1185-1193

[5] LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 [J].

Hacein-Bey-Abina, S ;

Von Kalle, C ;

Schmidt, M ;

McCcormack, MP ;

Wulffraat, N ;

Leboulch, P ;

Lim, A ;

Osborne, CS ;

Pawliuk, R ;

Morillon, E ;

Sorensen, R ;

Forster, A ;

Fraser, P ;

Cohen, JI ;

de Saint Basile, G ;

Alexander, I ;

Wintergerst, U ;

Frebourg, T ;

Aurias, A ;

Stoppa-Lyonnet, D ;

Romana, S ;

Radford-Weiss, I ;

Gross, F ;

Valensi, F ;

Delabesse, E ;

Macintyre, E ;

Sigaux, F ;

Soulier, J ;

Leiva, LE ;

Wissler, M ;

Prinz, C ;

Rabbitts, TH ;

Le Deist, F ;

Fischer, A ;

Cavazzana-Calvo, M .

SCIENCE, 2003, 302 (5644) :415-419

[6]

Howe Steven, 2003, Curr Hematol Rep, V2, P328

[7] Gene therapy with viral vectors [J].

Kootstra, NA ;

Verma, IM .

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2003, 43 :413-439

[8] Murine leukemia induced by retroviral gene marking [J].

Li, ZX ;

Düllmann, J ;

Schiedlmeier, B ;

Schmidt, M ;

von Kalle, C ;

Meyer, J ;

Forster, M ;

Stocking, C ;

Wahlers, A ;

Frank, O ;

Ostertag, W ;

Kühlcke, K ;

Eckert, HG ;

Fehse, B ;

Baum, C .

SCIENCE, 2002, 296 (5567) :497-497

[9] Site-specific genomic integration produces therapeutic Factor IX levels in mice [J].

Olivares, EC ;

Hollis, RP ;

Chalberg, TW ;

Meuse, L ;

Kay, MA ;

Calos, MP .

NATURE BIOTECHNOLOGY, 2002, 20 (11) :1124-1128

[10] Transcription start regions in the human genome are favored targets for MLV integration [J].

Wu, XL ;

Li, Y ;

Crise, B ;

Burgess, SM .

SCIENCE, 2003, 300 (5626) :1749-1751

← 1 →